Next-gen pacemaker hailed
ORLANDO, Fla. — Researchers are reporting encouraging results for a new generation of pacemakers — miniature, wireless ones that can be implanted through a leg vein without surgery.
In a study of 725 patients, one of these devices, made by Medtronic, was successfully implanted 99 percent of the time, with a low rate of complications compared to traditional pacemakers.
Leaders of the company-sponsored study discussed the research Monday at an American Heart Association conference in Orlando. Results also were published online by the New England Journal of Medicine.
Two months ago, the journal published a study of a similar device made by St. Jude Medical. Both of these mini pacemakers are already sold in Europe and the companies are seeking Food and Drug Administration approval to sell them in the U.S.
Roughly 200,000 people in the U.S. each year get a pacemaker, a device to regulate their heartbeats. Pacemakers are implanted just under the skin in the chest, with wires called leads that go into the heart. The wires can break, wear out or become infected and are the main weakness of these pacing systems.
The mini pacemaker is the size of a large pill and can be placed without surgery, through a tube into a blood vessel in the groin, and attached to the right side of the heart.
“I think it is a breakthrough,” said Dr. Douglas Zipes, a heart rhythm expert and past president of the American College of Cardiology. “Leads have been the Achilles’ heel of our implanted devices. To get rid of them will clearly benefit patients.”
That said, this is the first version of these devices, and they don’t do everything conventional pacemakers do. Only about one quarter of people who get pacemakers now would be candidates for the new mini ones. Future versions are expected to help more patients, and companies also are designing defibrillators that can be implanted without surgery as well.
Four percent of patients had major complications, including the device poking into the heart. Previous studies involving nearly 2,700 patients suggest this is roughly half the rate of complications usually seen.
